(Q40021043)

16 September 2017

title

BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism (English)

1 reference

16 September 2017

7

C Preudhomme

1 reference

16 September 2017

J Liu

1

1 reference

16 September 2017

S Joha

2

1 reference

16 September 2017

T Idziorek

3

1 reference

16 September 2017

S Corm

4

1 reference

16 September 2017

D Hetuin

5

1 reference

16 September 2017

N Philippe

6

1 reference

16 September 2017

B Quesnel

8

1 reference

16 September 2017

publication date

24 January 2008

1 reference

16 September 2017

number of pages

9

1 reference

inferred from page(s)

published in

Leukemia

1 reference

16 September 2017

volume

22

1 reference

16 September 2017

issue

4

1 reference

16 September 2017

page(s)

791-799

1 reference

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Janus kinase 2: a critical target in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Structure of the human Bim gene and its transcriptional regulation in Baf-3, interleukin-3-dependent hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

7 January 2021

Dormant Tumor Cells Develop Cross-Resistance to Apoptosis Induced by CTLs or Imatinib Mesylate via Methylation of Suppressor of Cytokine Signaling 1

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

7 January 2021

A new murine aggressive leukemic model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

7 January 2021

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.3

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.3

1 reference

Dimensions Publication ID

16 September 2017

1031739033

0 references

1 reference